4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary objective: safety and tolerability of BI 10773 in male and female patients with type
2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773